Endocyte, Inc. to Present at Upcoming Investment Conferences

Published on Wednesday, 08 February 2012 10:11 Written by TradersHuddle Staff

WEST LAFAYETTE, Ind., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that their company's management team will present at the following upcoming investment conferences:

Leerink Swann 2012 Global Healthcare Conference - Wednesday, Feb. 15, at 8:30 a.m. EST. The conference will be held at the Waldorf=Astoria in New York City.

Citi 2012 Global Health Care Conference – Monday, Feb. 27, at 3:00 p.m. EST. The conference will be held at the Waldorf=Astoria in New York City.

2012 RBC Capital Markets' Global Healthcare Conference – Tuesday, Feb. 28, at 9:30 a.m. EST. The conference will be held at the New York Palace in New York City.

Webcast information can be accessed under "Events & Presentations" in the Investor Relations section of Endocyte's website at www.endocyte.com. All webcasts will be archived shortly after each live event, and a replay will be available on the Company's website for 90 days following the conference.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

CONTACT: Stephanie Ascher
         Stern Investor Relations, Inc.
         (212) 362-1200
         
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
 
         
         Martina Schwarzkopf, Ph.D.
         Russo Partners
         (212) 845-4292
         
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
 
         
         Tony Russo, Ph.D.
         Russo Partners
         (212) 845-4251
         
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.